Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

Financial release accessible online

BOSTON, Nov. 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 2, 2023. The conference call and webcast can be accessed with the following information:

• Teleconference link: https://register.vevent.com/register/BI1dcb961b02424b85998e357a476fc7bf 
• Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
• A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/twgnwbaw

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.  

Direct link to 2Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/59b19d68-753c-4e39-a6c5-e2ea261b0658

A replay of the conference call and webcast will be available for one year beginning on November 2, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

SOURCE Haemonetics Corporation